BICYCLE THERAPEUTICS PLC
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
BCYC$3.69-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Equity
(In thousands, except share data)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Ordinary Shares · · Paid‑in · · Comprehensive · · Accumulated · · Shareholders’ | |||||||||||||||||
| · Shares · Amount · Capital · Income (Loss) · Deficit · Equity | |||||||||||||||||
| Balance at December 31, 2024 | | 69,061,418 | | $890 | | $1,472,842 | | $119 | | $(680,791) | | $793,060 | |||||
| Issuance of ADSs upon settlement of restricted share units | | 140,937 | | | 2 | | | — | | | — | | | — | | | 2 |
| Share-based compensation expense | | — | | | — | | | 9,605 | | | — | | | — | | | 9,605 |
| Foreign currency translation adjustment | | — | | | — | | | — | | | (1,580) | | | — | | | (1,580) |
| Net loss | | — | | | — | | | — | | | — | | | (60,754) | | | (60,754) |
| Balance at March 31, 2025 | | 69,202,355 | | $892 | | $1,482,447 | | $(1,461) | | $(741,545) | | $740,333 | |||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Ordinary Shares · · Paid‑in · · Comprehensive · · Accumulated · · Shareholders’ | |||||||||||||||||
| · Shares · Amount · Capital · Income (Loss) · Deficit · Equity | |||||||||||||||||
| Balance at December 31, 2023 | | 42,431,766 | | $550 | | $883,446 | | $(1,304) | | $(511,760) | | $370,932 | |||||
| Issuance of ADSs upon exercise of share options | | 133,735 | | | 2 | | | 1,868 | | | — | | | — | | | 1,870 |
| Issuance of ADSs upon settlement of restricted share units | | 67,096 | | | 1 | | | — | | | — | | | — | | | 1 |
| Share-based compensation expense | | — | | | — | | | 9,282 | | | — | | | — | | | 9,282 |
| Foreign currency translation adjustment | | — | | | — | | | — | | | 526 | | | — | | | 526 |
| Net loss | | — | | | — | | | — | | | — | | | (26,563) | | | (26,563) |
| Balance at March 31, 2024 | | 42,632,597 | | $553 | | $894,596 | | $(778) | | $(538,323) | | $356,048 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.